These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 30453303

  • 1. Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
    Papapetropoulos S, Liu W, Duvvuri S, Thayer K, Gray DL.
    Neurodegener Dis; 2018; 18(5-6):262-269. PubMed ID: 30453303
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
    Huang X, Lewis MM, Van Scoy LJ, De Jesus S, Eslinger PJ, Arnold AC, Miller AJ, Fernandez-Mendoza J, Snyder B, Harrington W, Kong L, Wang X, Sun D, Delnomdedieu M, Duvvuri S, Mahoney SE, Gray DL, Mailman RB.
    J Parkinsons Dis; 2020; 10(4):1515-1527. PubMed ID: 32986682
    [Abstract] [Full Text] [Related]

  • 4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 5. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Apr; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C, Torti M, Kieburtz K, Leinonen M, Vacca L, Grassini P, Heller A, Heller E, Stocchi F.
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA.
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ.
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [Abstract] [Full Text] [Related]

  • 20. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
    Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, Kegler-Ebo DM, Zhao P, Oh C.
    Parkinsonism Relat Disord; 2019 Jul; 64():175-180. PubMed ID: 30992235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.